Czechia, Feb. 12 -- Czechia based Gilead Sciences s.r.o. has secured contract from Fakultni nemocnice Plzen for Antineoplastic and immunomodulating agents - Medicinal preparation for autologous cell therapy - brexukabtagen autoleucel - 2025. The value of the contract is worth 10924985600 CZK.
Published by HT Digital Content Services with permission from Pivotal Sources....